Welcome!

News Feed Item

Molecular Medicine Awards 2nd Annual Ross Prize to NIH Scientist Dr. John O'Shea

Celebration and symposium to be held in New York on June 9

MANHASSET, N.Y., April 23, 2014 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that John J. O'Shea, MD, scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (NIH), will be the recipient of the second annual Ross Prize in Molecular Medicine. The Ross Prize is issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine. The Prize, which includes a $50,000 gift, will be formally presented to Dr. O'Shea on June 9 at the New York Academy of Sciences in Manhattan, followed by an academic lecture by Dr. O'Shea and several other preeminent researchers.

The Ross Prize is made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY. It is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

"John O'Shea turned his passion for clinical care into a successful research career pushing the frontiers of molecular medicine," said Feinstein Institute President, Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "His dedication and focus on the cytokine field have led to new treatments for immune diseases."

"It is very humbling to be awarded the 2014 Ross Prize in Molecular Medicine," said Dr. O'Shea. "From the beginning of my career, I was hoping to make discoveries that are important scientifically, but also directly help people – for me, it doesn't really get any better than that. It is very gratifying that my efforts to these ends are being recognized by this award."

On June 9, at a ceremony to be held at the New York Academy of Sciences in Manhattan, Dr. O'Shea will be presented the Ross Prize. After the award presentation, Dr. O'Shea; James P. Allison, PhD, The University of Texas MD Anderson Cancer Center; Louis M. Staudt, MD, PhD, National Cancer Institute, NIH; and Charles A. Dinarello, MD, University of Colorado at Denver, will each present scientific lectures. These preeminent researchers will discuss the mechanisms of immune system function and signaling, which may improve the treatment for cancer and various autoimmune diseases. To learn more about and register for the Ross Prize celebration and symposium, visit www.nyas.org/RossPrize2014. Registration is free.

Dr. O'Shea has been a physician and immunologist at NIH for 33 years. He has made fundamental discoveries related to the signaling of cytokines – molecules that are critical for the development and functioning of the immune system. His research also has focused on the molecular cause of primary immunodeficiencies, inherited conditions in which immune function is impaired, and the genetic basis of autoinflammatory disorders, conditions in which the body attacks its own tissues. He was awarded a US patent for his work on Janus family kinase inhibitors as a new class of immunosuppressive drugs. Dr. O'Shea developed a Cooperative Research and Development Agreement with the pharmaceutical company Pfizer, which generated one such compound that is approved for the treatment of rheumatoid arthritis. 

Dr. O'Shea graduated Phi Beta Kappa from St. Lawrence University, Canton, NY, and received his medical degree from the University of Cincinnati. After completing his residency in internal medicine at the State University of New York Upstate Medical University, Syracuse, he received subspecialty training in allergy and immunology at NIH. He was appointed chief of the NIAMS Molecular Immunology and Inflammation Branch in 2002, and became scientific director of the NIAMS Intramural Research Program in 2005. Dr. O'Shea has been the recipient of numerous awards and is a Fellow of the American Association for the Advancement of Science.

For the Ross Prize, Dr. O'Shea was selected by an awards committee comprised of:

  • Christopher J. Czura, PhD, vice president, scientific affairs, and executive editor, Molecular Medicine, Feinstein Institute for Medical Research;
  • Betty Diamond, MD, head, Center for Autoimmune Diseases and Musculoskeletal Disorders, Feinstein Institute;
  • Peter K. Gregersen, MD, head, Laboratory of Genomics and Human Genetics, Feinstein Institute;
  • Göran K. Hansson, MD, PhD, professor of experimental cardiovascular research, Karolinska Institute, Sweden;
  • Klas Kärre, MD, PhD, professor of molecular immunology, Karolinska Institute; and
  • Kevin J. Tracey, MD, president, Feinstein Institute.

About Molecular Medicine
Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to www.molmed.org.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit www.FeinsteinInstitute.org.

SOURCE The Feinstein Institute for Medical Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions with...
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager - Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, reviewed next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discussed how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has been engaged in t...
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
Every successful software product evolves from an idea to an enterprise system. Notably, the same way is passed by the product owner's company. In his session at 20th Cloud Expo, Oleg Lola, CEO of MobiDev, will provide a generalized overview of the evolution of a software product, the product owner, the needs that arise at various stages of this process, and the value brought by a software development partner to the product owner as a response to these needs.
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive ad...
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, discussed the best practices that will ensure a successful smart city journey.
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT depl...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
The pace of innovation, vendor lock-in, production sustainability, cost-effectiveness, and managing risk… In his session at 18th Cloud Expo, Dan Choquette, Founder of RackN, discussed how CIOs are challenged finding the balance of finding the right tools, technology and operational model that serves the business the best. He also discussed how clouds, open source software and infrastructure solutions have benefits but also drawbacks and how workload and operational portability between vendors an...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...